SBIROpen

Military Working Dog Whole Blood Product or Substitute

Solicitation ID26.BZ
Agency
DOD
DHA
Deadline
Jun 3, 2026
5 days left
Posted Date
Apr 13, 2026
Classification
SBIR
Phase: BOTH

SBIR Opportunity Analysis

The Defense Health Agency, through DoD SBIR topic DHA26BZ01-NV001, is seeking a shelf-stable canine whole blood product or substitute to improve hemorrhage control for Military Working Dogs after traumatic battlefield injury. The work calls for a solution that replicates whole blood oxygen-carrying performance and can be developed from feasibility through prototype and commercialization, with final product specifications and a path toward FDA Center for Veterinary Medicine approval. Key technical requirements include an oxygen capacity of about 24 ml/dL, a shelf life greater than three years, thermal stability from -9℃ to 60℃, and testing in suitable non-canine animal models rather than dogs. Phase II includes a powered in vivo comparison against crystalloid fluids, plasma, and whole blood in severe hemorrhage or hemorrhagic shock models, with outcomes such as survival, tissue oxygenation, coagulopathy correction, end organ function, and inflammatory or toxicity measures. The topic opened on May 6, 2026, and applications are due June 3, 2026 at 4:00 PM UTC under solicitation number 26.BZ.

SBIR Documents

1 Files
1776211344764.pdf
PDF74 KBMay 11, 2026
AI Summary
The DHA26BZ01-NV001 project aims to develop a shelf-stable whole blood product or substitute for Military Working Dogs (MWDs) to treat hemorrhage after battlefield injuries. This initiative supports the DoD Working Dog Strategic Research Plan, addressing the fact that uncontrolled bleeding accounts for over 45% of MWD battlefield deaths. The product must have a shelf-life exceeding three years and be thermally stable (-9℃ to 60℃), primarily replicating whole blood's oxygen-carrying capabilities. Phase I focuses on identifying a suitable solution with specific oxygen exchange and capacity characteristics, developing a testing plan using in vitro and non-canine in vivo models. Phase II involves developing the solution for large-scale production, conducting rigorous testing against current standards, and evaluating outcomes such as survival, tissue oxygenation, and coagulopathy correction. Phase III focuses on achieving FDA Center for Veterinary Medicine approval and commercialization for both military and civilian veterinary use.

Related SBIR/STTR Opportunities

Opportunity Snapshot

Source SystemOfficial Link
Program Type
SBIR - BOTH
Agency
DOD / DHA

Key Dates

Release DateApr 13, 2026
Open DateMay 6, 2026
Application DueJun 3, 2026
Close DateJun 3, 2026